Efficacy News and Research

RSS

CSL Biotherapies initiates clinical trials of Influenza A/H1N1 2009 vaccine in the US

CSL Biotherapies has announced the initiation of the company’s first U.S. clinical trials of its candidate Influenza A/H1N1 2009 vaccine. Study investigators will administer vaccinations to the first U.S. study volunteers today, August 24. The studies will determine the safety of CSL’s candidate vaccine and its ability to elicit an immune response (also referred to as immunogenicity) in adults and children.

24 Aug 2009

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

24 Aug 2009

Study reveals that increased neurostimulation market offers growth for device industries

The device industry would do well to focus on the treatment needs of individuals suffering from nerve-related disorders as implanted technologies that deliver electrical stimulation begin to supplant drugs for treating certain nerve-related disorders.

24 Aug 2009

Prescient Medical's vProtect(TM) Luminal Shield Stent System receives CE Mark approval for treating heart disorders

Medical device pioneer, Prescient Medical, Inc., announced today that it has received European CE Mark (Conformite Europeene) approval to commercialize its vProtect(TM) Luminal Shield Stent System. The device is now approved for use in improving coronary artery luminal diameter in patients with symptomatic ischemic heart disease.

24 Aug 2009

NovaBay Pharmaceuticals to deliver two poster presentations describing results from new studies of NVC-422

NovaBay(R) Pharmaceuticals, Inc., a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, will deliver two poster presentations at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

24 Aug 2009

Microbiologists discover new therapies for human respiratory syncytial virus and influenza A virus

A cellular molecule that not only can sense two common respiratory viruses but also can direct cells to mount a defense has been identified by microbiologists at The University of Texas Health Science Center at San Antonio.

24 Aug 2009

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients. Now the discovery of genetic biomarkers relevant to CRC means that targeted personalised medication is increasingly common.

24 Aug 2009

Applied Nanoscience in joint venture agreement to produce disposable protective face mask

Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration development company, today announced it has reached a joint venture agreement to begin production on a disposable protective face mask with its Asia Pacific region partner. The protective mask will incorporate ANI's proprietary NanoFense™ technology, a U.S. patent pending antimicrobial nanoparticle formulation.

21 Aug 2009

Physicians lack knowledge of off-label drug use and FDA approval status

In a recent national survey, a substantial minority of physicians erroneously believed that certain off-label uses of prescription drugs were approved by the Food and Drug Administration. This mistaken belief could encourage them to prescribe these drugs, despite the lack of scientific evidence supporting such use.

21 Aug 2009

Study finds that vaccinations to schoolchildren and to their parents helps to control the spread of the seasonal flu and H1N1

Optimal control of the spread of the seasonal flu and H1N1 is achieved by prioritizing vaccinations for schoolchildren and for adults aged 30 to 39 in the United States. Those are the findings of a new study by Clemson University mathematician Jan Medlock and colleague Alison Galvani of the Yale University School of Medicine.

21 Aug 2009

Bronchial asthma screening procedure for preschoolers still unreliable

The Institute for Quality and Efficiency in Health Care (IQWiG) has investigated the reliability of diagnosing bronchial asthma in children aged between 2 and 5 years, and the benefit that the test results can have for these patients. IQWiG published its final report in August 2009. According to the report, the available studies do not reveal any diagnostic procedure to be particularly suitable. It also remains unclear whether the treatment given based on the test results can benefit the patients.

21 Aug 2009

FDA permits Worldheart for bridge-to-transplant study of the Levacor Ventricular Assist Device

World Heart Corporation (WorldHeart) - (Nasdaq: WHRT) announced today that it has received FDA conditional approval to begin a bridge-to-transplant (BTT) study of the Levacor Ventricular Assist Device (VAD) at ten US centers.

21 Aug 2009

Advaxis awarded $210,000 for development of a dual antigen vaccine

Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been awarded a $210,000 grant from the US National Institute of Health (NIH) to develop a single bioengineered Lm vaccine to deliver two different antigen-adjuvant proteins.

20 Aug 2009

Peplin completes four-week enrolment phase for REGION-Ib trial

Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.

20 Aug 2009

New strategy found to increase the efficacy of protein-based drugs

A new method for attaching a large protective polymer molecule to a protein appears to improve protein drugs significantly.

20 Aug 2009

Eclipsemed collaborates with EndyMed Medical to market the FDA approved radio frequency device

Eclipsemed Ltd, a leading national distributor of advanced medical and aesthetic devices, is pleased to announce that they have collaborated with EndyMed Medical to market the superior EndyMed PRO radio frequency (RF) device to the United States.

20 Aug 2009

Research reveals effectiveness of carvedilol in preventing variceal hemorrhage

Patients with cirrhosis are at risk for developing portal hypertension that can lead to the formation, dilation, and rupture of esophageal varices. The annual incidence of esophageal varices is approximately 5% and one third of those will bleed.

20 Aug 2009

Valensa International's technology increases shelf-life and stability of astaxanthin

Valensa International announced today that it has developed technology that has dramatically increased the stability and shelf-life of the powerful, versatile antioxidant astaxanthin. The company has just completed a 7-year shelf-life study of its Zanthin(R) natural astaxanthin that indicates that this ultra-high pressure supercritical CO2 extract of Haematococcus pluvialis, bolstered by Valensa's proprietary O2B(R) Peroxidation Blocker technology, has a minimum 4-year shelf-life.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Imagenetix announces retail distribution of InflameAway Celadrin(R) gels for promoting joint health

Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced that InflameAway Celadrin(R) extra strength soft gels for joint health are currently available at the nation's number one drug chain, the number one and number two supermarket stores and the number one club warehouse store. This retail distribution provides a platform for future retail gains as well as additional product launches, including a 100 count value size.

20 Aug 2009

Efficacy News and Research

CSL Biotherapies initiates clinical trials of Influenza A/H1N1 2009 vaccine in the US

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Study reveals that increased neurostimulation market offers growth for device industries

Prescient Medical's vProtect(TM) Luminal Shield Stent System receives CE Mark approval for treating heart disorders

NovaBay Pharmaceuticals to deliver two poster presentations describing results from new studies of NVC-422

Microbiologists discover new therapies for human respiratory syncytial virus and influenza A virus

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Applied Nanoscience in joint venture agreement to produce disposable protective face mask

Physicians lack knowledge of off-label drug use and FDA approval status

Study finds that vaccinations to schoolchildren and to their parents helps to control the spread of the seasonal flu and H1N1

Bronchial asthma screening procedure for preschoolers still unreliable

FDA permits Worldheart for bridge-to-transplant study of the Levacor Ventricular Assist Device

Advaxis awarded $210,000 for development of a dual antigen vaccine

Peplin completes four-week enrolment phase for REGION-Ib trial

New strategy found to increase the efficacy of protein-based drugs

Eclipsemed collaborates with EndyMed Medical to market the FDA approved radio frequency device

Research reveals effectiveness of carvedilol in preventing variceal hemorrhage

Valensa International's technology increases shelf-life and stability of astaxanthin

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Imagenetix announces retail distribution of InflameAway Celadrin(R) gels for promoting joint health

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News